To Deliver Low Dose Intravenous Ketamine for Mood and Anxiety Disorders, a Recommended Treatment by Canadian Guidelines, Upon Clinic LicensingOAKVILLE, ON / ACCESSWIRE / March 23, 2022 / NeonMind Biosciences
Data Further Validates Psilocybin as a Drug Candidate for Obesity and Supports Development of NeonMind's Drug Programs NEO-001 and NEO-002OAKVILLE, ON / ACCESSWIRE / March 23, 2022 / NeonMind Biosciences
OAKVILLE, ON / ACCESSWIRE / March 22, 2022 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) ("NeonMind' or the "Company"), an integrated drug development and wellness company focused on bringing
NeonMind Files New Provisional Patent Application Covering Novel Mechanism of Weight Loss streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.